Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
609A
DRUG
3 trials
Sponsors
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions
Sarcoma, Soft Tissue
Solid Tumors
Phase 1
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A
NCT03950297
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Solid Tumors
Start: 2019-05-01
End: 2022-05-24
Target: 24
Updated: 2020-04-03
Phase 2
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
NCT05138146
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Sarcoma, Soft Tissue
Start: 2021-12-30
End: 2024-12-30
Target: 70
Updated: 2021-11-30
Unknown Phase
Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China
NCT03998345
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Solid Tumors
Start: 2020-07-25
End: 2020-12-30
Target: 24
Updated: 2020-09-09